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Abstract
Bioluminescence imaging is routinely performed in anesthetized mice. Often isoflurane anesthesia is used because of its
ease of use and fast induction/recovery. However, general anesthetics have been described as important inhibitors of the
luciferase enzyme reaction.
Aim: oinvestigatefrequentlyusedmouseanestheticsfortheirdirecteffectonthe luciferasereaction,both invitroandinvivo.
Materials and Methods: isoflurane, sevoflurane, desflurane, ketamine, xylazine, medetomidine, pentobarbital and avertin
were tested in vitro on luciferase-expressing intact cells, and for non-volatile anesthetics on intact cells and cell lysates. In
vivo, isoflurane was compared to unanesthetized animals and different anesthetics. Differences in maximal photon emission
and time-to-peak photon emission were analyzed.
Results: All volatile anesthetics showed a clear inhibitory effect on the luciferase activity of 50% at physiological
concentrations. Avertin had a stronger inhibitory effect of 80%. For ketamine and xylazine, increased photon emission was
observed in intact cells, but this was not present in cell lysate assays, and was most likely due to cell toxicity and increased
cell membrane permeability. In vivo, the highest signal intensities were measured in unanesthetized mice and pentobarbital
anesthetized mice, followed by avertin. Isoflurane and ketamine/medetomidine anesthetized mice showed the lowest
photon emission (40% of unanesthetized), with significantly longer time-to-peak than unanesthetized, pentobarbital or
avertin-anesthetized mice. We conclude that, although strong inhibitory effects of anesthetics are present in vitro, their
effect on in vivo BLI quantification is mainly due to their hemodynamic effects on mice and only to a lesser extent due to
the direct inhibitory effect.
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Introduction
Bioluminescence imaging (BLI) has emerged over the last
decades as a non-invasive assessment of a molecular target. A
luciferase reporter gene is expressed in cells of interest and the
enzymatic turnover of luciferase after administration of its
substrate allows the readout of the reporter gene activity. The
signal intensity reflects the strength or changes of a molecular
target in a quantitative way. In vivo, many other parameters can
influence the BLI readout, such as the administration route and
protein binding of the substrates, overlying tissues characteristics
and membrane pumps that can remove substrates out of the cell
[1,2,3,4,5,6].
During BLI, anesthesia of mice and rats is performed to reduce
changes is signal intensity due to movement of the animal.
However, a direct inhibitory effect of some general anesthetics on
the luciferase enzyme has been described in literature. Already in
1976, the inhibitory effect of local anesthetics on firefly luciferase
(Fluc) was reported [7]. Since then, the interaction of Fluc with
anesthetics has been considered the best-characterized model
system for studying anesthetic–protein interactions [8,9,10]. This
research revealed that several local and general anesthetics have
an inhibitory effect on the luciferase activity by direct binding to
the enzyme, at concentrations similar to those that induce general
anesthesia in animals [11,12]. Whether the binding of the
inhibitor is substrate-competitive or non-competitive has been
long debated and has not reached a consensus thus far. Recently,
the hypothesis that some anesthetics can not only bind at the D-
luciferin binding site, but also to a domain that regulates the
opening and closing of the enzymatic pocket has been proposed.
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TBinding of anesthetics to this domain results in closing of the
enzymatic cleft and it therefore inhibits the binding of D-luciferin
[13].
Besides a potential direct inhibitory effect of the luciferase
reaction, anesthetics influence the cardiovascular condition of the
test animal, thereby potentially altering the delivery of the
substrate to the cells of interest and thus the BLI signal intensity
[14]. The effect of general anesthetics on BLI in vivo has so far only
been investigated in a small comparative study by Cui et al., in
which isoflurane and avertin led to lower BLI signals compared to
ketamine/xylazine [15]. We hypothesize, based on these previ-
ously reported direct and indirect effects of anesthetics, that
general anesthetics, used during BLI, will affect the intensity and
kinetics of the bioluminescent signal in vivo.
The aim of this study was to investigate the effect of different
currently used mouse anesthetics on a Fluc-expressing cell line,
both in vitro and in vivo. We here show that, although strong
luciferase-inhibiting effects of anesthetics are present in vitro for
volatile agents and avertin, their effect on in vivo BLI quantification
is mainly due to their hemodynamic effect on the mice and only to
a lesser extent due to a direct effect on the luciferase enzyme itself.
For high sensitivity, unanesthetized BLI or BLI using pentobar-
bital are the most suited, followed by avertin. Isoflurane, although
very user friendly, as well as ketamine/medetomidine anesthesia
reduce sensitivity. Thorough standardization of the anesthesia,
both in dosage and time between induction and substrate
injection, should improve the reproducibility of the technique.
Materials and Methods
Ethics statement
The study protocol was approved by the Institutional Animal
Care and Use Committee of Vrije Universiteit Brussel, permit
number 10-272-3, and National Institutes of Health principles of
laboratory animal care (NIH publication 86-23, revised 1995)
were followed.
Cell lines
The commercial vector pGL4.10 (Promega, Madison, WI,
USA), encoding Firefly luciferase (Fluc) and the thermostable red-
shifted Firefly luciferase (Ppy RE–TS), kindly provided by
Branchini et al. [16], were constitutively expressed in a R1M
rhabdomyosarcoma cell line (R1M-Fluc) and 293T cell line (293T-
Fluc) respectively, as was previously described [4,17]. R1M-Fluc
cells were grown in Minimal Essential Medium (MEM) with 10%
fetal bovine serum (FBS), 1% non-essential amino acids, 100 U/
mL penicillin, 100 mg/mL streptomycin and 0.13 mg/mL fungi-
zone (all from Invitrogen, Paisley, UK). 293T-Fluc cells were
grown in Dulbecco’s modified Eagle medium (DMEM) supple-
mented with 100 U/mL penicillin, 100 mg/mL streptomycin,
2 mM L-glutamine (all from Lonza, Verviers, Belgium) and 10%
FBS (Biochrom AG, Berlin, Germany).
Substrates
D-luciferin (Promega, Madison, WI, USA) was diluted in
phosphate buffered saline (PBS) to obtain a stock solution of
30 mg/ml, after which the solution was sterilized using a 0.22 mm
filter for in vivo use.
Anesthetics
For all anesthetics, a literature search was performed to
document the conventional in vivo doses for mice. For volatile
anesthetics, these doses are reported as minimum alveolar
concentration or MAC. MAC is the concentration of a volatile
anesthetic that is needed to prevent movement in 50% of subjects
in response to pain stimulus [18]. A lower MAC value represents a
more potent inhalation anesthetic. For surgical procedures, a
concentration of 1.2–1.56MAC is usually used. Table 1 shows the
corresponding MAC values per volatile anesthetic [19,20,21,22].
For injectable anesthetics, doses are expressed in mg/kg.
Conventionally used doses are shown in Table 2 [23,24,25]. For
in vitro use, we converted these doses to mg/L, assuming a
homogenous distribution of the anesthetic in the whole body and a
mass density of mice of 1 L/kg. The in vivo dose range is indicated
in the figures using grey intervals.
Following stock solutions of anesthetics were used: isoflurane (1-
chloro-2,2,2-trifluoroethyl-difluoromethyl ether, Forene, Abbott,
England); sevoflurane (fluoromethyl 2-2 difluoro 1-trifluoromethyl
vinyl ether, Sevorane, Abbott, England), desflurane (2,2,2-
trifluoro-1-fluoroethyl-difluoromethyl ether, Suprane, Baxter,
Belgium); 100 mg/ml ketamine hydrochloride (Ketamine 1000
CEVA, CEVA Sante ´ Animale); 20 mg/mL xylazine (Rompun
2%, Bayer, Belgium); 60 mg/ml natrium pentobarbital (Nembu-
tal, CEVA Sante ´ Animale, Belgium); 1 mg/ml medetomidine
hydrochloride (Medetor, Virbac, Belgium). Avertin (2,2,2-tribro-
moethanol) was purchased from Sigma-Aldrich (Germany) and
5 g was dissolved in 2-methyl-2-butanol (Sigma-Aldrich) to obtain
a stock concentration of 1.6 g/mL by stirring overnight at room
temperature protected from light. This stock solution was further
dissolved in 0.9% NaCl to obtain a final concentration of 20 mg/
mL (overnight stirring at room temperature protected from light),
after which the solution was sterilized using a 0.22 mm filter, kept
at 4uC protected from light and was used within 1 month after
dissolution.
In vitro intact cell BLI measurements
For in vitro measurements, R1M-Fluc cells were plated in normal
growth medium in 25 cm
2 culture flasks (1610
6 cells/flask) or 24-
well plates (75610
3 cells/well). After overnight incubation at 37uC
and 5% CO2 to allow adherence, cells were preincubated with the
Table 1. Physiological anesthetic ranges for volatile
anesthetics.
Anesthetic agent MAC in vivo dose range references
Isoflurane 1.2–1.8% 1.6–2.3% [32,33]
Sevoflurane 2.2–2.9% 2.9–3.8% [34,35]
Desflurane 6.5–9.1% 8.5–11.8% [33]
MAC=minimum alveolar concentration.
doi:10.1371/journal.pone.0030061.t001
Table 2. Physiological anesthetic ranges for injectable
anesthetics.
Anesthetic agent in vivo dose range references
Ketamine 18–200 mg/kg [36,37], IACUC
Xylazine 5–20 mg/kg [37], IACUC
Pentobarbital 40–70 mg/kg [38], IACUC
Medetomidine 0.5–1.0 mg/kg [36], IACUC
Avertin 200–400 mg/kg IACUC
IACUC=Institutional Animal Care and Use Committee.
doi:10.1371/journal.pone.0030061.t002
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2
culture flasks were used. A continuous flow of oxygen with the
appropriate percentage of inhalation anesthetic above the media
was created. The following volatile anesthetics were used
(concentrations indicated in brackets): isoflurane (0.0%, 0.5%,
1.0%, 1.5%, 2.0%, 2.5%, 3.0%); sevoflurane (0.0%, 0.5%, 1.0%,
1.5%, 2.0%, 2.5%, 3.5%, 5.0%); desflurane (0.0%, 1.0%, 3.0%,
6.0%, 9.0%, 12%, 18%, 21%).
For injectable anesthetics, 24-well plates were used. The cell
medium was replaced by fresh cell medium containing the
appropriate concentration of the anesthetic. The following
injectable anesthetics were used (final concentrations indicated in
parentheses): ketamine (0.0 mg/L, 20 mg/L, 100 mg/L, 200 mg/
L, 400 mg/L); xylazine (0.0 mg/L, 4.0 mg/L, 10 mg/L, 20 mg/
L, 40 mg/L); pentobarbital (0.0 mg/L, 14 mg/L, 50 mg/L,
70 mg/L, 140 mg/L); medetomidine (0.0 mg/L, 0.10 mg/L,
0.50 mg/L, 1.0 mg/L, 2.0 mg/L); avertin (0.0 mg/L, 48 mg/L,
120 mg/L, 240 mg/L, 480 mg/L).
BLI measurements were performed as described in [4].
Measurements were started immediately after the addition of the
substrate (final concentration of D-luciferin: 0.15 mg/ml), in the
presence of the anesthetic, using a Photo Imager camera
(Biospace, France) that allows list mode acquisition. Experiments
were performed in triplicate (inhalation anesthetics) or quadrupli-
cate (injectable anesthetics). Identical circular Regions of Interest
(ROI) were drawn over the wells and their Photon emission (PE)
using 5 sec intervals was analyzed. The maximum photon
emission (PEmax) of the dynamic profile of 10 minutes containing
the peak photon emission was derived using the 95
th percentile.
Per condition, an average of 9 (inhalation anesthesia) or 12
(injectable anesthesia) samples (3 experiments performed in
triplicate/quadruplicate) is expressed as % of control 6 standard
deviation (SD).
pH of anesthetic solutions in cell media was assessed using pH-
indicator strips pH 4.0–7.0 and 6.5–10.0 (Merck, Darmstadt,
Germany).
In vitro cell lysate BLI measurements
To analyze the effect of injectable anesthetics on the luciferase
reaction in the absence of cell membranes, which might interfere
with the diffusion of the substrate into the cells, results of the intact
cell measurements were compared to those obtained on cell
lysates. A commercially available Luciferase Assay Reagent
(promega) was used, which contains all necessary substrates for
the reaction in excess [26].
In a white 96-well plate, 1610
4 R1M-Fluc cells were added to
50 mL of Reporter Lysis Buffer (Promega) per well, and a single
freeze-thaw cycle was performed. Per well, 10 mL of injectable
anesthetics were added at appropriate concentrations to reach
final concentrations, identical to the concentrations used in the
intact cell measurements. Measurements were performed using a
glomax-96 microplate luminometer with auto-injector system
(Promega). BLI intensity was measured at baseline (before
addition), and with a 10 s delay after the addition of 50 mLo f
Luciferase Assay Reagent, using the automated injector. The
integration time was set at 5 s for all measurements. For further
analysis, values after addition of the Luciferase Assay Reagent
were corrected by subtracting the baseline signal. Per condition,
an average of 12 samples (3 experiments performed in quadru-
plicate) is expressed as % of control 6 SD.
Mice
Male athymic nude (Hsd:Athymic Nude-Foxn1
nu) mice were
purchased from Harlan Laboratories (Boxmeer, The Netherlands)
and were between 5 and 11 weeks old before initiation of
experiments. Mice were kept in individually ventilated cages
(Techniplast, Buguggiate, Italy) on sawdust on a 12-h day/night
cycle with water and food ad libitum.
In vivo BLI
293T-Fluc cells (1610
6 cells in matrigel) were subcutaneously
injected in mice at day 0 during a short anesthesia with
isoflurane. Mice were imaged at day 3, 5 and 7 post cell
injection, alternating between isoflurane anesthesia (2%) and the
test anesthetic with a cross over design, so that half of the mice
had twice isoflurane and half of the mice had twice the test
anesthetic [3]. For the final signal intensity, the average of day 3
and day 7 was compared to day 5, to correct for cell growth
between the different imaging sessions. Four anesthetic conditions
were compared to isoflurane in 4 different groups of mice: no
anesthesia (n=10); ketamine 37.5 mg/kg/medetomidine
0.5 mg/kg (n=12) [27]; pentobarbital 60 mg/kg (n=14) [28];
avertin 400 mg/kg (n=12) [29]. Injectable anesthetics were
injected intraperitoneally without induction anesthesia. After a
brief induction with 2% isoflurane anesthesia, or when mice were
non-reactive after injection of the test anesthetic, D-luciferin was
injected intravenously at a weight-dependent substrate dose of
150 mg/kg.
Immediately after substrate administration, mice were imaged
using the Photon Imager (Biospace, France). For unanesthetized
imaging, the photon imager was equipped with the in actio
module (Biospace), which simultaneously records both biolumi-
nescence signal and a bright field video of the animal under
infrared illumination for co-registration (Fig S2 and video S1).
Mice were placed inside the BLI camera on a heated platform to
maintain a physiological body temperature. Using a nose cone,
volatile anesthetics in O2 or 100% O2 were administered during
the entire acquisition. The photon emission was measured
dynamically during 45 min, except for the isoflurane/unanes-
thetized study, for which the acquisition duration was 50 min.
For image analysis an elliptical ROI was drawn over the mouse
bearing the 293T-Fluc cells. The surface area of the ROI was
kept constant. A time activity curve for every acquisition was
obtained by analyzing images in 5 s intervals. For the
calculation of the PEmax from the tumor, the 95
th percentile
of 5 s intervals was used, as was described previously [4]. All
anesthetics and the unanesthetized imaging were compared to
the conventionally used isoflurane anesthesia (2%) and are
expressed as % of this control condition. For the calculation of
the time-to-peak, the same acquisition data were analyzed using
1 min intervals, and the time point containing the highest
photon emission was defined as time-to-peak. For the isoflur-
ane/unanesthetized study, the area under the curve (AUC) was
calculated over 50 min by making the sum of all 5 s intervals
a n de x p r e s s e da s%o fi s o f l u r a n e .
Statistical analysis
All data are represented as mean 6 SD. Statistical analysis was
carried out in Prism 5.0 (GraphPad software Inc.). Unpaired t test
was used to compare means of 2 groups for in vitro experiments. In
vivo BLI intensity data were analyzed using two-tailed Wilcoxon
signed rank tests for each test anesthetic in comparison to
isoflurane (4 groups of mice). Time-to-peak of different anesthetics
was compared in all the groups of mice taken together using a
Kruskal-Wallis test and a Dunn’s multiple comparison test. A p
value,0.05 was considered to be significant.
Effect of Anesthetics on BLI Signal Intensity
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For all anesthetics, the effect on in vitro luciferase activity of
physiological in vivo dose ranges is summarized in Table 3.
Volatile anesthetics in vitro
In a first part, we sought to investigate if a direct inhibitory
effect, as was already described for halothane on pure luciferase
enzyme, could be detected for regularly used volatile mouse
anesthetics in intact cells as well [30]. Fluc expressing R1M cells
were allowed to adhere in small culture flasks overnight. They
were incubated with a continuous flow of a mixture of oxygen and
the volatile anesthetic above the cell media during 10 min, after
which D-luciferin was added and photon emission (PE) was
measured. A preliminary study showed no difference in biolumi-
nescent signal obtained from cells using incubation with 100%,
95%, 50% or 25% O2 (Fig. S1). At the end of the experiment, cells
were analyzed microscopically, which showed no change in
morphology of the cells. Results for the three volatile anesthetics
tested are shown in Figure 1. For isoflurane, the most often used
volatile anesthetic in mice, there is an important decrease in the
bioluminescent signal with increasing amounts of isoflurane
(Fig. 1A), indicating an important and dose-dependent inhibitory
effect. Within the physiological dose range for isoflurane, signal
intensities drop to 50.4–65.8% of control values. Sevoflurane
showed the most pronounced inhibitory effect, with average
signals of 57.0–51.3% at 1.36 MAC (Fig. 1B). Results for
desflurane are comparable to isoflurane, with a drop in signal
intensity to 56.8–65.0% at 1.36MAC (Fig. 1C).
Injectable anesthetics in vitro
Since inhibitory effects were also described for injectable
anesthetics such as lidocaine, we further wanted to analyze if
regularly used mouse anesthetics for injection showed a direct
inhibitory effect on the luciferase reaction [31]. Cells were plated
in well plates and incubated in the presence of the anesthetic
during 10 min, after which the substrate D-luciferin was added
and bioluminescent signals were quantified. Since for some
anesthetics, an increase rather than a decrease in BLI signal was
detected, the results were further supplemented with experiments
using cell lysates and the commercially available luciferase assay
kits containing all the substrates needed for the bioluminescent
reaction, to evaluate if a change in diffusion through the cell
membrane was responsible for the observed increase in BLI signal.
Cells were also evaluated morphologically by light microscopy at
the end of BLI. R1M rhabdomyosarcoma cells grow adherent and
have a fibroblast-like spindle shape in normal conditions.
The effects of ketamine and xylazine on PE are shown in
Figure 2. An increase in PE is seen with increasing amounts of the
anesthetic, up to 288% for the highest used dose of ketamine.
However, this effect is abrogated when cell lysates are used instead
of intact cells, indicating that the increase in bioluminescent signal
is due to a higher cell membrane permeability. When evaluating
the intact cells morphologically after BLI, signs of cell toxicity,
such as cell rounding and detachment, were noticed. This effect
was detected for 200 and to a stronger extent for 400 mg/L
ketamine. Below 200 mg/L ketamine, no changes were seen in cell
morphology. For xylazine, this effect was less pronounced and only
present at the highest concentration. These changes in cell
morphology indicate a toxic effect on the cells.
For pentobarbital and medetomidine, there is no significant
effect in the in vivo dose ranges (Fig. 3). Figure 3A shows a decrease
in PE for high doses of pentobarbital in the intact cell assay, but
not for cell lysates. This indicates a possibly weak inhibitory effect
on the luciferase enzyme, only at supraphysiological concentra-
tions, that is no longer present in the cell lysate assay, since then
higher doses of the substrates are used. There were no changes in
cell morphology at the end of the experiment.
To test the effect of avertin that is dissolved in the vehicle 2-
methyl-2-methanol, both the vehicle and the combination with
avertin were tested. As shown in Figure 4, there is a very strong
effect in intact cells, which is mainly due to avertin itself, but the
Table 3. In vitro BLI at physiological anesthetic range.
Anesthetic
agent In vivo dose range average % of untreated cells
intact cells cell lysate
Isoflurane 1.6–2.3% 65.8–50.4%
Sevoflurane 2.9–3.8% 57.0–51.3%
Desflurane 8.5–11.8% 65.0–56.8%
Ketamine 18–200 mg/kg 114–164% 101–102%
Xylazine 5–20 mg/kg 107–147% 96.4–98.8%
Pentobarbital 40–70 mg/kg 104–101% 106–104%
Medetomidine 0.5–1.0 mg/kg 103–109% 97.3–98.5%
Avertin 200–400 mg/kg 24.1–15.6% 58.3–38.8%
doi:10.1371/journal.pone.0030061.t003
Figure 1. Effect of volatile anesthetics on BLI signal. The effect on photon emission (PE) of isoflurane (A), sevoflurane (B) and desflurane (C)
anesthetics is expressed relative to control samples, containing 100% oxygen without inhalation anesthetic. Intact cells were used. Grey intervalsi n
the curves indicate the in vivo dose ranges.
doi:10.1371/journal.pone.0030061.g001
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cell lysates are used, the effect is no longer present for the vehicle,
and only moderately for vehicle+avertin, suggesting that the
higher amounts of substrates in this assay can partly overcome the
inhibitory effect. At microscopic evaluation, no changes in cell
morphology were observed at the end of the experiment.
To exclude any effect of a change in pH due to the addition of
anesthetics to the cell media, pH of the highest anesthetic
concentration was compared to media without anesthesia and
no change in pH above 0.5 was detected.
The inhibitory effect of isoflurane and avertin was also
quantified in 293T-Fluc cells, which were used in in vivo
experiments, with an inhibitory effect comparable to that observed
in R1M-Fluc cells (data not shown).
Reversibility of inhibitory effect by higher substrate
concentration
In literature, there has been some controversy about the
underlying mechanism of luciferase inhibition by anesthetics,
being (non-)competitive or (non-)reversible. To further investigate
this question, we examined the effect of increased substrate
concentrations on the inhibitory effect of anesthetics. The intact
cell assay was repeated with 106 higher doses of D-luciferin for
both isoflurane and avertin, at doses at which PE was reduced to
around 50% of control values (2% isoflurane and 48 mg/L
avertin). Figure 5 shows that the inhibition can partly be overcome
by using D-luciferin at 1500 mg/L instead of 150 mg/L, to 88%
and 77% of control values for isoflurane and avertin respectively.
This result indicates that the effect is reversible but non-
competitive, since the reversibility is not complete.
In vivo comparison of anesthetics
To compare the effect of anesthesia on BLI in vivo, the
bioluminescent signal obtained using different anesthetics was
intra-individually compared to isoflurane, serving as the standard.
Isoflurane anesthesia was also compared to unanesthetized mice.
Isoflurane was chosen as the standard because bioluminescence
cameras are all equipped with gas anesthesia inlet and outlet ports,
resulting in the majority of BLI measurements being performed
using isoflurane anesthesia. In unanesthetized animals, variations
in the signal over time was noted due to movement of the animal,
making this method less suited as the standard. An example of the
Figure 2. Effect of ketamine and xylazine on BLI signal of intact cells and cell lysates. The effect on photon emission (PE) of the
anesthetics ketamine (A) and xylazine (B) are shown using intact cells (full line) and cell lysates (dotted line). All data are represented as mean % of
control (absence of anesthetic) 6 SD. Grey intervals in the curves indicate the concentrations used in vivo, as reported in literature for mice.
doi:10.1371/journal.pone.0030061.g002
Figure 3. Effect of pentobarbital and medetomidine on BLI signal of intact cells and cell lysates. The effect on photon emission (PE) of
the anesthetics pentobarbital (A) and medetomidine (B) are shown using intact cells (full line) and cell lysates (dotted line). All data are represented
as mean % of control (absence of anesthetic) 6 SD. Grey intervals in the curves indicate the concentrations used in vivo, as reported in literature for
mice.
doi:10.1371/journal.pone.0030061.g003
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supplementary data (Fig. S2 and video S1).
Figure 6A displays the differences in peak bioluminescent signal
using different or no anesthetics, normalized to the obtained value
for isoflurane (100%). It clearly shows that unanesthetized animals
as well as pentobarbital-anesthetized mice have a significantly
higher peak signal than using isoflurane anesthesia (256%,
p=0.002; 254%, p=0.009 respectively). This effect is less
pronounced for avertin anesthesia (156%, p=0.009). The
combination of ketamine/medetomidine anesthesia gives a signal
intensity that is comparable to isoflurane anesthesia (104%, ns).
This intensity is on average 40% of unanesthetized and
pentobarbital-anesthetized signal intensities, indicating a clear
negative effect of these anesthetic conditions on the bioluminescent
peak signal.
Not only the intensity of the signal was evaluated in these mice,
but also the time that elapsed between the injection of the
substrate D-luciferin and the time of the maximal signal intensity,
termed ‘‘time to peak’’. Figure 6B reflects the time of the peak for
all performed acquisitions according to the used anesthetic
condition. There was a significantly later peak for ketamine/
medetomidine and isoflurane as compared to avertin, pentobar-
bital and unanesthetized animals.
Although there was a clear difference in time to peak for
different anesthetic conditions, the overall amount of light
produced, calculated by the AUC of the time activity curve,
might still be the same. To investigate this hypothesis, peak signal
intensities were compared to AUC values for mice imaged with
isoflurane anesthesia and without anesthesia. Representative time
activity curves of 1 mouse are shown in Figure 7A, showing a fast
rise and a more rapid decline in the BLI signal for the
unanesthetized acquisition compared with 2% isoflurane. In
Figure 7B, the average of all mice for peak intensity is compared
to total PE, calculated as the AUC during 50 minutes, for both
anesthetic conditions. The difference in BLI signal between the
two conditions is indeed less pronounced when AUC is calculated
(146% for AUC compared to 256% for peak photon emission), but
it is still significantly higher in unanesthetized animals (p=0.002),
showing that not only the peak signal but also the total amount of
signal produced is different in these two anesthetic conditions. For
isoflurane and ketamine/medetomidine, there was no significant
difference in the AUC values (p=0.46, data not shown).
Using avertin and pentobarbital, mice usually woke up before
the end of the acquisition and started moving around inside the
camera between 30 and 40 min after tracer injection. This finding
does not allow a correct calculation of the AUC for avertin and
pentobarbital. When pentobarbital was used, mice often remained
responsive to pain stimuli at the time of D-luciferin injection.
Discussion
Bioluminescence imaging is a recently improved imaging
technique that allows in vivo quantitative assessment of the reporter
gene activity in small animals such as mice and rats, after the
administration of its substrate. It allows easy transition from in vitro
reporter assay systems using the luciferase gene to analysis of these
Figure 4. Effect of avertin and its vehicle on BLI signal of intact
cells and cell lysates. The effect on photon emission (PE) of the
anesthetic avertin (black) and its vehicle 2-methyl-2-butanol (grey) are
shown using intact cells (full line) and cell lysates (dotted line). All data
are represented as mean % of control (absence of anesthetic) 6 SD. The
grey interval in the curve indicates the concentration used in vivo,a s
reported in literature for mice.
doi:10.1371/journal.pone.0030061.g004
Figure 5. Reversibility of photon emission inhibition by high substrate concentration. Photon emission and its inhibition by isoflurane (A)
and avertin (B) was examined at normal concentration of D-luciferin (D-luc 150 mg/L) and a 106higher concentration (D-luc 1500 mg/L) to assess
the reversibility of the inhibition. * p,0.05, ** p,0.01, *** p,0.0001.
doi:10.1371/journal.pone.0030061.g005
Effect of Anesthetics on BLI Signal Intensity
PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e30061same phenomena in living mice. Mice are anesthetized during the
imaging to avoid movement artifacts within the acquired data.
Often volatile anesthetics are chosen because of their ease of use.
Isoflurane anesthesia units are now routinely provided together
with most BLI cameras on the market.
Many anesthetics, such as halothane and lidocaine, have
however been proven to exert a direct inhibitory effect upon the
luciferase enzyme by binding to the protein and changing the
catalytic velocity of the enzyme, either in a competitive or non-
competitive way [11]. We therefore wanted to investigate and
characterize the possible inhibitory effect of different types of
volatile anesthetics as well as injectable anesthetics that are
frequently used in rodents. In a second part, we wanted to
correlate these in vitro findings to changes in signal intensities and
kinetics in mice using different anesthetic conditions.
For volatile anesthetics, the results clearly show a dose-
dependent inhibitory effect on the bioluminescent reaction of
about 50% for all three agents, making neither sevoflurane nor
desflurane better alternatives for the frequently used isoflurane.
For the injectables ketamine and xylazine, we found the opposite
effect, with a dose-dependent increase in bioluminescent signal,
which was associated with a microscopic change in cell
morphology pointing towards a toxic effect of these agents. We
therefore hypothesized that the toxic effect was changing the cell
membrane permeability for the substrate D-luciferin, leading to
higher intracellular substrate concentrations and thereby a higher
bioluminescent signal. This was confirmed by the abrogation of
the effect in the absence of the cell membrane barrier, using cell
lysate assays. The injectable avertin caused a powerful inhibition
of the luciferase reaction of about 80% at physiological
concentrations in intact cells. The effect was less pronounced but
still clear in the cell lysate assays, most likely because of the higher
substrate concentrations in the cell lysate assay. For pentobarbital
and medetomidine, no effect on the luciferase reaction was
Figure 6. In vivo comparison of anesthetics. (A) represents the maximum BLI intensity obtained from the same mice anesthetized with
isoflurane or the test anesthetic mentioned below the curve. Values were normalized to isoflurane signal intensities. (B) shows a scatter plot of the
time to the peak signal intensity for the different anesthetics. Each data point represents a unique bioluminescent acquisition from the in vivo
comparison of anesthetics study. Lines indicate the mean. There was a significantly later peak for ketamine/medetomidine and isoflurane as
compared to avertin, pentobarbital and unanesthetized animals. ** p,0.01 between indicated conditions; { p,0.05 compared to both isoflurane and
ketamine/medetomidine.
doi:10.1371/journal.pone.0030061.g006
Figure 7. Comparison of peak signal and AUC of the signal for isoflurane-anesthetized and unanesthetized mice. (A) shows a
representative example of the time profile obtained using isoflurane anesthesia (full line) and without anesthesia (dotted line). (B) shows the average
peak signal and AUC of the signal for the same mice, anesthetized with isoflurane or without anesthesia. ** p,0.01 between indicated conditions. AUC
area under the curve.
doi:10.1371/journal.pone.0030061.g007
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measurements and cell lysate assays.
We further investigated the reversibility of the inhibition of
isoflurane and avertin by challenging the inhibition with a 10-
times higher substrate dose. This showed a partially reversible
inhibition for both compounds, pointing towards a mixed-type
inhibition. This type of luciferase inhibition has been explained by
Szarecka et al., as a combination of competitive binding at the
substrate binding sites as well as a non-competitive binding at a
hinging region of the luciferase enzyme, thereby altering the
accessibility of the enzymatic pocket for its substrates [13]. Higher
doses of substrate can result in an increased chance to bind within
the enzymatic pocket, but will never reach the turnover that is
obtained in het absence of the mixed-type inhibitor.
Of course, the most important question is to what extent these
inhibitors can influence in vivo BLI quantification. In in vivo settings,
not only a direct effect can be of influence, but also the effect of the
anesthetic agent on the cardiovascular condition of the mouse is
likely to change the delivery of the substrate to the luciferase-
expressing tissue. We therefore compared isoflurane, the most
frequently used anesthetic for in vivo BLI, to different anesthetic
combinations as well as to BLI in unanesthetized mice. The latter
was possible by using a dedicated system that allows the
simultaneous recording of both bioluminescence signal and a
bright field video of the animal under infrared illumination for co-
registration (Fig. S2 and video S1). Movement of the mouse
however causes changes in the overlying tissues, resulting in
fluctuation in the observed signal over time, as can be seen in the
curve of Fig. 7A.
When comparing the maximal signal intensities observed using
different anesthetic conditions, unanesthetized and pentobarbital
anesthetized BLI result in the highest photon emission. Avertin
resulted in a lower maximal photon emission than unanesthetized
or pentobarbital anesthetized BLI, but still significantly higher
than the intensities obtained using isoflurane and ketamine/
medetomidine. The majority of these results do not correspond to
the inhibition that was measured in vitro, where the lowest
intensities were obtained for avertin, and no negative effect was
observed for ketamine or medetomidine. Only for isoflurane, the
inhibition detected in vitro correlates well with low in vivo signal
intensities. Other factors than merely the direct inhibitory effect
must therefore play an important role in in vivo BLI.
When comparing the maximal in vivo signal intensities to the
time to peak, high peak values are associated with short time to
peak values, indicating that a fast biodistribution of the substrate
leads to higher bioluminescent signals. This finding suggests that
cardiovascular changes, caused by the anesthetics, induce
differences in substrate biodistribution, which alters both maximal
signal intensity as well as signal kinetics. A similar observation was
made by Cui et al., where ketamine/xylazine resulted in the
highest peak photon emission and shortest time to peak. Contrary
to our findings, they report equally low values for avertin-
anesthetized and isoflurane-anesthetized mice, which might be
explained by the lower anesthetic doses that were used.
Pentobarbital and avertin anesthesia resulted in shorter
anesthesia duration, with waking up of the mice after 30–
40 min. These conditions gave the highest signal intensities, for
pentobarbital comparable to unanesthetized mice and for avertin
to about 2/3 of unanesthetized animals. In literature, avertin has
been named as one of the most suitable anesthetics for functional
cardiac assessment since it decreases heart rate to a much lesser
extent than ketamine/xylazine anesthesia [20,22]. Other anes-
thetics with limited effect on heart rate and cardiac output are
isoflurane and to a lesser extent pentobarbital [19,21,23,25].
Among these 3 anesthetics, the lowest BLI signal intensities were
obtained using isoflurane and avertin, which suggests that a direct
inhibitory effect on the enzymatic reaction could also be partly
responsible for their lower BLI intensity compared to unanesthe-
tized and pentobarbital-anesthetized mice. This however remains
uncertain since we do not possess information about the
cardiovascular condition and tissue perfusion in our mouse study.
Ketamine/medetomidine anesthesia, as well as isoflurane,
provided the lowest signal intensities. The combination of
ketamine with another alpha2-agonist, xylazine, induces a strong
reduction in heart rate and therefore cardiac output, as was
already shown in multiple mouse studies [19,21,23,24]. Data are
less abundant for the longer acting ketamine/medetomidine
combination, but effects are expected to be comparable to
ketamine/xylazine [14]. This strong reduction in cardiac output
most likely causes a decreased D-luciferin delivery to the
luciferase-expressing cells, resulting in lower signal intensities and
slower kinetics.
Besides the cardiovascular effect, another factor that might
explain the differences observed between in vitro and in vivo results
is the dilution and distribution of the anesthetics. We assumed a
perfectly homogenous distribution of the anesthetics in mice, but
given their lipophilicity, concentrations will be higher in fatty
tissues, such as brain and fat, and lower at the subcutaneous
luciferase expression site.
For isoflurane-anesthetized and unanesthetized animals, we not
only compared maximum BLI signal but also looked at total
photon emission by calculating AUC. Total photon emission was
still significantly lower in the isoflurane group, although the
difference was smaller. This finding might suggest that AUC is a
better parameter to assess luciferase expression levels than peak
photon emission, but given the prolonged acquisition times
necessary to obtain this value, in our case up to 50 min, it is
unlikely this will be the parameter of choice for future
experiments.
To achieve maximal sensitivity in in vivo BLI, imaging
unanesthetized mice is preferable. Disadvantages however include
movement artifacts and changes in attenuation by the overlying
tissues, causing fluctuations in the intensity that is measured.
Moreover, sources at the lateral or ventral side of the mouse will
be difficult to image because of the important amount of overlying
tissues. The latter however can be overcome by using a 3D
dynamic camera, allowing a multiple-view dynamic imaging of a
moving mouse. Other sensitive options include pentobarbital and
to a lesser extent avertin anesthesia. Isoflurane, although very user-
friendly, as well as ketamine/medetomidine are less suited to
achieve high sensitivity for in vivo BLI. Since cardiovascular effects
of ketamine/xylazine are expected to be similar to those of
ketamine/medetomidine, it does not hold promise as a good
candidate either.
Once the anesthetic approach has been chosen, a thoroughly
standardized imaging protocol, including bodyweight-adapted
anesthetic dose and a fixed time interval between the induction
of the anesthesia and time of substrate injection, should improve
reproducibility of the method, by reducing the interfering effects of
the anesthesia on the signal intensity.
We conclude that, although strong luciferase-inhibiting effects
of anesthetics are present in vitro for volatile agents and avertin,
their effect on in vivo BLI quantification is mainly due to their
hemodynamic effect on the mice and only to a lesser extent due to
a direct effect on the luciferase enzyme itself. For high sensitivity,
unanesthetized BLI or BLI using pentobarbital are the most
suited, followed by avertin. Isoflurane, although very user friendly,
as well as ketamine/medetomidine anesthesia reduce sensitivity.
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time between induction and substrate injection, should improve
the reproducibility of the technique.
Supporting Information
Figure S1 Comparison of BLI intensity using different
fractions of oxygen. 1610
6 R1M-Fluc cells were plated in small
culture flasks and were allowed to adhere overnight. Starting
10 min before BLI measurements, cells were incubated with a
continuous flow of either 100% O2 or a mixture of different
fractions of oxygen in N2 above the cell media. Quantification of
the BLI signal intensity showed no significant differences (n=4).
(TIF)
Figure S2 Principles of unanesthetized imaging. (A)‘ ‘ in
actio’’ module that is inserted into the camera to enable the
imaging of unanesthetized mice. (B) Representation of the module.
The registration video is done using a near-infrared (NIR) camera
and a near-infrared laser for illumination. A dichroic beam splitter
allows direct transmission (with 95% efficiency) of the biolumi-
nescence signal while reflecting the NIR light at an angel of 90u.
(C) Principle of the dynamic fusion of video data and
bioluminescence data. (D) The Laser and the intensified camera
are switched on and off in opposition. When the laser is switch on,
the intensifier camera is switched off and vice versa. The laser is
switched on 1.5 ms every 22 ms, with a delay of 0.5 ms after the
extinction of the laser. The intensified camera is then acquiring the
bioluminescent signal during 20 ms every 22 ms. CCD charge-
coupled device. ICCD intensified CCD. IR infrared. Figure from PhD
thesis of Mickae ¨l Savinaud entitled [Registration of the flux in
kinematic data: application in optical imaging], in French.
(TIF)
Video S1 Unanesthetized BLI. Imaging in unanesthetized
mice was achieved by using a dedicated system that allows the
simultaneous recording of both bioluminescence signal and a
bright field video of the animal under infrared illumination for co-
registration. This video shows an example of a mouse bearing
293T-Fluc cells at the neck region after the injection of D-luciferin.
For quantification, the same large region of interest covering the
whole area of movement was used for both unanesthetized and
anesthetized imaging.
(AVI)
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